Analysis of cell height in the tall cell subtype of papillary thyroid carcinoma. Is it a key factor in the prognosis?

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion Pub Date : 2025-03-01 DOI:10.1016/j.endien.2025.101530

Ricard Onieva Carbajo , Joan Carles Ferreres Piñas , Flavia Alberto , Ismael Capel Flores , Martina Pérez , Maria Rosa Bella Cueto

{"title":"Analysis of cell height in the tall cell subtype of papillary thyroid carcinoma. Is it a key factor in the prognosis?","authors":"Ricard Onieva Carbajo , Joan Carles Ferreres Piñas , Flavia Alberto , Ismael Capel Flores , Martina Pérez , Maria Rosa Bella Cueto","doi":"10.1016/j.endien.2025.101530","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>The tall cell subtype of papillary thyroid carcinoma (PTC) is considered to have poor prognosis, but its diagnostic criteria have been modified on several occasions. The aim of our study was to find the best diagnostic criteria to relate the tall cell subtype with aggressiveness and poor prognosis.</div></div><div><h3>Material and methods</h3><div>In 171 cases of classic subtype and tall cell subtype of PTC, the percentage of cells between two and three times taller than wide (C2−3) and cells more than three times taller than wide (Cx3) was determined by two observers, after obtaining reference images. Groups were made based on the percentage of cells of each component (<2%, between 2 and 10%, between 11 and 30%, between 31 and 50% and >50%) and were correlated with clinical and histopathological data. Interobserver agreement was also assessed.</div></div><div><h3>Results</h3><div>According to the current WHO classification criteria, only 8 cases (5%) of tall cell subtype were identified. The comparison of the risk of recurrence at 5 years based on the percentage and type of cells showed that it increased significantly from >10% of the Cx3 cell component, while there were no significant differences in recurrence rate with any C2−3 cell percentages. Very good interobserver agreement was obtained (Kappa index: 0.83).</div></div><div><h3>Conclusions</h3><div>We consider relevant reporting the presence of Cx3 cells from 10% in PTC as it is associated with a significant increase in the recurrence rate at 5 years. Interobserver agreement is very good if reference images are available.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 3","pages":"Article 101530"},"PeriodicalIF":1.8000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinologia Diabetes Y Nutricion","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2530018025000277","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

The tall cell subtype of papillary thyroid carcinoma (PTC) is considered to have poor prognosis, but its diagnostic criteria have been modified on several occasions. The aim of our study was to find the best diagnostic criteria to relate the tall cell subtype with aggressiveness and poor prognosis.

Material and methods

In 171 cases of classic subtype and tall cell subtype of PTC, the percentage of cells between two and three times taller than wide (C2−3) and cells more than three times taller than wide (Cx3) was determined by two observers, after obtaining reference images. Groups were made based on the percentage of cells of each component (<2%, between 2 and 10%, between 11 and 30%, between 31 and 50% and >50%) and were correlated with clinical and histopathological data. Interobserver agreement was also assessed.

Results

According to the current WHO classification criteria, only 8 cases (5%) of tall cell subtype were identified. The comparison of the risk of recurrence at 5 years based on the percentage and type of cells showed that it increased significantly from >10% of the Cx3 cell component, while there were no significant differences in recurrence rate with any C2−3 cell percentages. Very good interobserver agreement was obtained (Kappa index: 0.83).

Conclusions

We consider relevant reporting the presence of Cx3 cells from 10% in PTC as it is associated with a significant increase in the recurrence rate at 5 years. Interobserver agreement is very good if reference images are available.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrinologia Diabetes Y Nutricion Multiple-

CiteScore

2.10

自引率

10.50%

发文量

期刊介绍： Endocrinología, Diabetes y Nutrición is the official journal of the Spanish Society of Endocrinology and Nutrition (Sociedad Española de Endocrinología y Nutrición, SEEN) and the Spanish Society of Diabetes (Sociedad Española de Diabetes, SED), and was founded in 1954. The aim of the journal is to improve knowledge and be a useful tool in practice for clinical and laboratory specialists, trainee physicians, researchers, and nurses interested in endocrinology, diabetes, nutrition and related disciplines. It is an international journal published in Spanish (print and online) and English (online), covering different fields of endocrinology and metabolism, including diabetes, obesity, and nutrition disorders, as well as the most relevant research produced mainly in Spanish language territories. The quality of the contents is ensured by a prestigious national and international board, and by a selected panel of specialists involved in a rigorous peer review. The result is that only manuscripts containing high quality research and with utmost interest for clinicians and professionals related in the field are published. The Journal publishes Original clinical and research articles, Reviews, Special articles, Clinical Guidelines, Position Statements from both societies and Letters to the editor. Endocrinología, Diabetes y Nutrición can be found at Science Citation Index Expanded, Medline/PubMed and SCOPUS.